The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jon Wolleben - Citizens JMP Securities, LLC - Analyst
: Congrats on the progress. A couple for me. You talked a little bit about improved responses in VITESSE. I was hoping you could talk a little bit how
that translates also to what you expect for the placebo arm in that study. Can you -- wondering if you'd talk about the planning of the start of
COMFORT Toddlers.
And then lastly, the relative unmet need in the four- to seven-year-old, which could come earlier, versus the one- to three-year-old population. So
I guess those three would be great to hear from.
Question: Jon Wolleben - Citizens JMP Securities, LLC - Analyst
: Is there any way you can quantify what you expect, so in placebo response in the prior trial versus what you expect here as well? And I'm sure you
still think the delta is greater but -- so you're expecting a more robust response just in the Viaskin Peanut arm versus the placebo here?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Jon Wolleben - Citizens JMP Securities, LLC - Analyst
: Yes. And then can you talk about kind of start-up activities for COMFORT Toddlers?
Question: Sam Slutsky - LifeSci Capital LLC - Analyst
: Congrats on all the recent progress. A couple for me. I guess, obviously, the Xolair launch has exceeded expectations in food allergy. Could you
just discuss the read-through from this on the market opportunity as a whole in food allergy and then consideration for the Xolair within the
competitive landscape for Viaskin Peanut? And then I have one more question after.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Sam Slutsky - LifeSci Capital LLC - Analyst
: And then just last question. For the two age groups for Viaskin Peanut, are those BLAs linked in any way? Or are they completely distinct, their
submissions?
Question: Sushila Hernandez - - Analyst
: I just have one. Does the departure of Peter Marks have any material impacts on the regulatory part of Viaskin Peanut in toddler or children?
| 
